- Source type
- Study
- Access type
- Publisher
- Publisher
- New England Journal of Medicine
- Date
- 2024
- Added
- 2026-06-19
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
88
Peer-reviewed research publisher
- Publisher type
- Peer-reviewed journal
- Bias profile
- Moderate
This source is strongest for clinical outcomes and mechanism and weaker for regulatory status and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 65/100
- Context Source
- Clinical outcomes
- 92/100
- Primary Anchor
- Mechanism
- 90/100
- Primary Anchor
- Safety
- 86/100
- Strong Support
- Consumer context
- 72/100
- Context Source
- Trial discovery
- 65/100
- Context Source
Best used for
- Primary studies
- Systematic reviews
- Mechanistic research
Weak for
- Regulatory status
- Universal consumer recommendations
Used in Viral Vitalism
FLOW
Roles: Primary source
Show section-level references
GLP-1s Are Not Just a Weight Loss Story
Roles: Primary source
Show section-level references
Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes
Roles: Primary source
Show section-level references
Claim ledger
Claims supported
Reviewed claim cards that cite this source in the evidence graph.
semaglutide: Semaglutide improved kidney outcomes in FLOW participants with type
Semaglutide improved kidney outcomes in FLOW participants with type 2 diabetes and chronic kidney disease.
glp 1: GLP-1-based therapies have demonstrated outcome benefits beyond weight loss
GLP-1-based therapies have demonstrated outcome benefits beyond weight loss in specific high-risk cardiometabolic populations.
Related studies
Related sources
FLOW trial: semaglutide and chronic kidney disease outcomes
PubMed used across the Viral Vitalism evidence library.
- Trust score
- 91
- Publisher
- PubMed
- Indexed by
- PubMed
- Access
- Abstract/index
- Usage
- 3 connections
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder
Trial registry for oral semaglutide among adults with AUD.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
Does Semaglutide Reduce Alcohol Intake
Trial registry for semaglutide and alcohol intake.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
Effects of Semaglutide on Nicotine Intake
Trial registry for semaglutide and nicotine intake.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 2 connections
ESSENCE clinical trial registry
ClinicalTrials.gov used across the Viral Vitalism evidence library.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 3 connections
ESSENCE phase 3 trial design for semaglutide in MASH
PubMed used across the Viral Vitalism evidence library.
- Trust score
- 91
- Publisher
- PubMed
- Indexed by
- PubMed
- Access
- Abstract/index
- Usage
- 2 connections